Jump to content

MK-2206

Add links
From Wikipedia, the free encyclopedia
MK-2206
Names
Preferred IUPAC name
8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f] [1,6]naphthyridin-3(2H)-one
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.207.435 Edit this at Wikidata
EC Number
  • 682-246-4
UNII
  • InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)
    Key: ULDXWLCXEDXJGE-UHFFFAOYSA-N
  • InChI=1/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)
    Key: ULDXWLCXEDXJGE-UHFFFAOYAX
  • C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N
Properties
C25H21N5O
Molar mass 407.477 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C25H21N5O.[1] It acts as an allosteric AKT inhibitor.[2]

It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3.[1]

It is intended to be used with other cancer therapies that advanced tumours may become resistant to.[3]

Clinical trials

[edit]

2011: A phase 1 clinical trial of MK-2206 alone has reported it was well tolerated.[4]
2014: A phase 1 clinical trial of MK-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects.[3]
2016: MK-2206 is one of the treatments in the I-SPY2 Adaptive clinical trial for breast cancer that had been selected for later stage trials.[5]
As of August 2017 31 phase II clinical trials are registered, many completed.[6] e.g. in colorectal cancer, breast cancer, and many others.

MK-2206 and COVID-19

[edit]

Data shown in a study preprint suggest that SARS-CoV-2 infection decreases cellular autophagy and that MK-2206, which induces autophagy, reduced virus replication by up to 88% in vitro. The study's authors propose that MK-2206 should be tested in clinical trials as a potential treatment for COVID-19.[7]

References

[edit]
  1. ^ a b MK-2206 dihydrochloride (CAS 1032350-13-2) inc structure diagram
  2. ^ MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Hirai et al. 2010
  3. ^ a b A trial of MK-2206 with chemotherapy or erlotinib for advanced cancer
  4. ^ Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. (December 2011). "First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors". Journal of Clinical Oncology. 29 (35): 4688–4695. doi:10.1200/JCO.2011.35.5263. PMID 22025163.
  5. ^ Novel Agents are Targeting Drivers of TNBC - Several drug candidates in I-SPY2 have 'graduated' to later-phase studies. June 2016
  6. ^ MK-2206 phase=2 trials
  7. ^ Gassen NC, Papies J, Bajaj T, Emanuel J, Dethloff F, Chua RL, et al. (June 2021). "SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals". Nature Communications. 12 (1): 3818. doi:10.1038/s41467-021-24007-w. PMC 8217552. PMID 34155207.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MK-2206&oldid=1144344313"